Ecopipam

Drug Profile

Ecopipam

Alternative Names: Ecopipam HCl; PSYRX 101; SCH-39166

Latest Information Update: 20 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Psyadon Pharmaceuticals; Schering-Plough; University of California Riverside School of Medicine
  • Class Antipsychotics; Benzazepines; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lesch-Nyhan syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lesch-Nyhan syndrome
  • Phase II Gilles de la Tourette's syndrome
  • Preclinical Speech disorders
  • No development reported Gambling
  • Discontinued Cocaine abuse; Obesity; Schizophrenia

Most Recent Events

  • 12 Jul 2017 Restless Legs Syndrome Foundation plans a phase I/II trial for Restless legs syndrome in USA (NCT03218969) in July 2017
  • 17 Jan 2017 Psyadon completes enrolment in its phase II trial for Gilles de la Tourette's syndrome (In adolescent, In children) in USA
  • 20 Sep 2016 Preclinical trials in Speech disorders in USA before September 2016 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top